Showing studies matching your search11 results shown

Studies (11 shown)

NCT06270719ENROLLING_BY_INVITATION

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

Sponsor · Sarepta Therapeutics, Inc.Condition · Duchenne Muscular DystrophyIntervention · Delandistrogene Moxeparvovec, Standard of CareUpdated May 2026
NCT05881408PHASE3ACTIVE_NOT_RECRUITING

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Sponsor · Sarepta Therapeutics, Inc.Condition · Duchenne Muscular DystrophyIntervention · delandistrogene moxeparvovec, placeboUpdated May 2026
NCT06128564PHASE2ACTIVE_NOT_RECRUITING

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

Sponsor · Hoffmann-La RocheCondition · Duchenne Muscular DystrophyIntervention · delandistrogene moxeparvovecUpdated May 2026
NCT04626674PHASE1RECRUITING

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Sponsor · Sarepta Therapeutics, Inc.Condition · Muscular Dystrophy, DuchenneIntervention · delandistrogene moxeparvovecUpdated Apr 2026
NCT05967351PHASE3ENROLLING_BY_INVITATION

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Sponsor · Sarepta Therapeutics, Inc.Condition · Duchenne Muscular DystrophyIntervention · delandistrogene moxeparvovecUpdated Feb 2026
NCT06241950PHASE1TERMINATED

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Sponsor · Sarepta Therapeutics, Inc.Condition · Duchenne Muscular DystrophyIntervention · delandistrogene moxeparvovec, imlifidaseUpdated Nov 2025
NCT06597656PHASE1TERMINATED

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Sponsor · Sarepta Therapeutics, Inc.Condition · Duchenne Muscular DystrophyIntervention · delandistrogene moxeparvovec, PlasmapheresisUpdated Sep 2025
NCT05096221PHASE3COMPLETED

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Sponsor · Sarepta Therapeutics, Inc.Condition · Duchenne Muscular DystrophyIntervention · delandistrogene moxeparvovec, placeboUpdated Jul 2025
NCT03375164PHASE1, PHASE2COMPLETED

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Sponsor · Sarepta Therapeutics, Inc.Condition · Duchenne Muscular DystrophyIntervention · delandistrogene moxeparvovecUpdated Nov 2024
NCT03769116PHASE1, PHASE2COMPLETED

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

Sponsor · Sarepta Therapeutics, Inc.Condition · Muscular Dystrophy, DuchenneIntervention · delandistrogene moxeparvovec, placeboUpdated Nov 2024
NCT07542314PHASE4NOT_YET_RECRUITING

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

Sponsor · Sarepta Therapeutics, Inc.Condition · Duchenne Muscular DystrophyIntervention · ELEVIDYS, SirolimusUpdated May 2026
Showing top 11 results. See all 11 results on CT.gov →